Jazz Pharmaceuticals vs Organon
Organon reported revenue of $6.2 billion in fiscal 2025, 1.5 times Jazz Pharmaceuticals' $4.3 billion in fiscal 2025. Jazz Pharmaceuticals' revenue grew 4.9% in its latest year, and Organon's fell 2.9%. Free cash flow was $1.3 billion at Jazz Pharmaceuticals and $538 million at Organon.
Side by side
| Jazz Pharmaceuticals | Organon | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4.3B | $6.2B |
| Revenue growth | 4.9% | −2.9% |
| Revenue growth a year, last 5 years | 12.5% | −1.0% |
| Gross margin | — | 53.3% |
| Operating margin | −10.1% | — |
| Net margin | −8.3% | 3.0% |
| Free cash flow | $1.3B | $538M |
| Free cash flow margin | 30.4% | 8.7% |
| Return on capital | −4.2% | 5.3% |
| Net debt to EBITDA | — | 6.3x |
| Dividends and buybacks | $125M | $88M |
| Change in diluted share count | −7.6% | 0.6% |
| Last close | $205.70 | $13.74 |
| P/E at the last close | 14.1× | 17.6× |
| Insider trades, last 12 months | sold $68.0 million | bought $854,704, sold $200,307 |
| Piotroski F-score | 4 of 8 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Jazz PharmaceuticalsOrganon
Operating margin
Percent of revenue
Jazz PharmaceuticalsOrganon
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Jazz PharmaceuticalsOrganon
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Jazz Pharmaceuticals and Organon pages.